Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
5.57
-0.09 (-1.59%)
Nov 16, 2026, 4:00 PM EST - Market closed
Myriad Genetics Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Myriad Genetics stock has a consensus rating of "Hold" and an average price target of $5.90. The average 1-year stock price forecast is 5.92% higher than the current stock price, while the lowest is $3.80 (-31.78%) and the highest is $8.00 (+43.63%).
Price Target: $5.90 (+5.92%)
Analyst Consensus: Hold
Price Target
ChartAnalyst Ratings
The average analyst rating for Myriad Genetics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 5 | 4 | 5 | 5 | 6 | 6 |
| Sell | 1 | 1 | 1 | 2 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 9 | 8 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens | Stephens | Hold Reiterates $6 | Hold | Reiterates | $6 | +7.72% | Nov 12, 2026 |
| Piper Sandler | Piper Sandler | Hold Reiterates $5 | Hold | Reiterates | $5 | -10.23% | Nov 10, 2026 |
| Bank of America Securities | Bank of America Securities | Sell Maintains n/a | Sell | Maintains | n/a | n/a | Nov 5, 2026 |
Unknown Analyst Leerink Partners No rating | Leerink Partners | Hold Maintains $5 → $8 | Hold | Maintains | $5 → $8 | +43.63% | Nov 5, 2026 |
| TD Cowen | TD Cowen | Hold Reiterates $4.5 → $6.75 | Hold | Reiterates | $4.5 → $6.75 | +21.18% | Nov 5, 2026 |
Financial Forecast
Revenue This Year
786.05M
from 824.50M
Decreased by -4.66%
Revenue Next Year
719.79M
from 786.05M
Decreased by -8.43%
EPS This Year
-0.70
from 0.06
EPS Next Year
-0.61
from -0.70
EPS and Forward PE are based on non-GAAP adjusted numbers.